Clinical Trial Update: Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of isatuximab and cemiplimab in relapsed or refractory Natural Killer/T-cell lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Natural Killer T-cell Lymphoma

Drugs mentioned

• Cemiplimab (cemiplimab)
• Isatuximab (isatuximab)

Snippet

Sponsor: Won Seog Kim | Conditions: Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma | Phase 2 | Status: COMPLETED